Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cutaneous Leishmaniasis Reinfection: Skin Disease and Leishmaniasis Research Center, Isfahan, Iran



Jaffary F1 ; Nilforoushzadeh MA2 ; Abdellahi L3 ; Mortazaei S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan and Skin and Stem cell Research Center Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Skin and Stem cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Parasitology School of Medicine, Kerman University of Medical Sciences, Kerman AND Skin Diseases and Leishmaniasis Research Center Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2015

Abstract

Background: Cutaneous leishmaniasis is a self-limited disease that does not cause a major problem in terms of death and disability compared to other diseases. However, permanent disfiguring scar, longterm period of wound healing, secondary infection, drug side effects, treatment duration and secondary effects caused by the drugs increase the impact of the burden of this disease. This study was designed to investigate the status of cutaneous leishmaniasis reinfection in patients referred to Skin Disease and Leishmaniasis Research Center (SDLRC), Isfahan, Iran. Methods: Demographic information such as age, sex, number and place of lesion, migration to endemic areas, nationality, and occupation of the patients with cutaneous leishmaniasis referred to Skin Disease and Leishmaniasis Research Center parasitology laboratory in the years of 2012 and 2013 was collected.Findings: Of 1087 patients diagnosed as having cutaneous leishmaniasis, 75 patients (6.8%) had reinfection. Mean age of these patients was 34.73 ± 20.91 years (ranging 1-75). Women (41, 54.7%) were affected more than the men (34, 45.3%) with no statistically significant difference. Conclusion: Some patients with the history of cutaneous leishmaniasis may suffer reinfection after several years of recovery. Less than 10% of patients had this problem in the our study population. Several factors such as genotype or strain variations and immune deficiency due to chronic backgrounds may be involved in the process of reinfection. Further researches are warranted to explore the underlying pathophysiology. © 2010, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. The Skin Side Effects of Topical Glucantime in Patients With Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2015)
2. Epidemiology and Clinical Features of Cutaneous Leishmaniasis in Badrood City, Iran, in 2013, Journal of Isfahan Medical School (2015)
3. The Epidemiology of Cutaneous Leishmaniasis in Isfahan Province, Iran, During 2001-2011, Journal of Isfahan Medical School (2015)
4. Evaluation of Leishmanin Skin Test and Its Relationship With the Clinical Form and Duration of Cutaneous Leishmaniasis, Dermatology Online Journal (2006)
5. Identification of Leishmania Isolates From Healing and Nonhealing Cutaneous Leishmaniasis Patients Using Internal Transcribed Spacer Region Pcr, Jundishapur Journal of Microbiology (2014)
6. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
7. Identification and Isolation of the Cause of Cutaneous Leishmaniasis in Isfahan Using Its-Pcr Method, Journal of Isfahan Medical School (2012)
8. Comparing the Effects of Topical Miltefosine and Glucantime in Treatment of Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2014)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (51)
Ali Asilian (17)
Other Related Docs
9. The Epidemiology of Cutaneous Leishmaniasis in Ardestan City, Iran, During the Years 2012 to 2019, Journal of Isfahan Medical School (2020)
10. Identification and Isolation of the Cause of Cutaneous Leishmaniasis in Isfahan Using Its-Pcr Method, Journal of Isfahan Medical School (2012)
11. Evaluation of Il-12Rb1, Il-12B, Cxcr-3 and Il-17A Expression in Cases Affected by a Non-Healing Form of Cutaneous Leishmaniasis: An Observational Study Design, BMJ Open (2017)
12. The Efficacy of Treatment With Intralesional Meglumine Antimoniate Alone, Compared With That of Cryotherapy Combined With the Meglumine Antimoniate or Intralesional Sodium Stibogluconate, in the Treatment of Cutaneous Leishmaniasis, Annals of Tropical Medicine and Parasitology (2003)
13. Comparison Between the Efficacy of Photodynamic Therapy and Topical Paromomycin in the Treatment of Old World Cutaneous Leishmaniasis: A Placebo-Controlled, Randomized Clinical Trial, Clinical and Experimental Dermatology (2006)
14. Treatment of Recurrent Cutaneous Leishmaniasis, International Journal of Dermatology (1995)
15. A Comparison of the Effects of Topical Injection of Glucantime Plus Glycolic Acid 70% and Salicylic Acid 20% With Topical Injection of Glucantime Alone in the Treatment of Acute Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2017)
16. The Efficacy of Intralesional Meglumine Antimoniate (Glucantime) Versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2012)
17. Comparison Between the Efficacy of Photodynamic Therapy and Topical Paromomycin in the Treatment of Old World Cutaneous Leishmaniasis: A Placebo-Controlled, Randomized Clinical Trial, Indian Journal of Dermatology (2006)
18. Molecular Epidemiological Survey of Cutaneous Leishmaniasis in Two Highly Endemic Metropolises of Iran, Application of Fta Cards for Dna Extraction From Giemsa-Stained Slides, Jundishapur Journal of Microbiology (2016)
19. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran, Archives of Iranian Medicine (2020)
20. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
21. Effect of Combination Therapy With Systemic Glucantime and Pentoxifylline in the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2006)
22. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
23. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Itraconazole in the Treatment of Cutaneous Leishmaniasis, Journal of the European Academy of Dermatology and Venereology (2005)
24. Reevaluating Leishmanin Skin Test As a Marker for Immunity Against Cutaneous Leishmaniasis, International Journal of Dermatology (2013)
25. Comparison Between the Efficacy of Photodynamic Therapy and Topical Paromomycin in the Treatment of Old World Cutaneous Leishmaniasis: A Placebo-Controlled, Randomized Clinical Trial, Journal of Isfahan Medical School (2012)
26. A New Focus of Zoonotic Cutaneous Leishmaniasis in Shiraz, Iran, Transactions of the Royal Society of Tropical Medicine and Hygiene (2009)
27. Treatment of Cutaneous Leishmaniasis With Ketoconazole Cream, Journal of Dermatological Treatment (2003)
28. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Research in Medical Sciences (2012)
29. Clinical Picture of Cutaneous Leishmaniasis in Isfahan, Iran, International Journal of Dermatology (1994)
30. Isolation of Bacteria Causing Secondary Bacterial Infection in the Lesions of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2008)
31. Demographic and Clinical Characteristics of Children With Cutaneous Leishmaniasis in Isfahan Province, Iran, During 2011-2015, Journal of Isfahan Medical School (2017)
32. Comparative Effect of Topical Trichloroacetic Acid and Intralesional Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, International Journal of Pharmacology (2006)
33. Evaluation of Leishmanin Skin Test Reaction in Different Variants of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2013)
34. Effect of Topical Honey Application Along With Intralesional Injection of Glucantime in the Treatment of Cutaneous Leishmaniasis, BMC Complementary and Alternative Medicine (2007)
35. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2013)
36. The Efficacy of 5% Trichloroacetic Acid Cream in the Treatment of Cutaneous Leishmaniasis Lesions, Journal of Dermatological Treatment (2012)
37. Comparison of Intralesionally Injected Zinc Sulfate With Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, Dermatology (2004)
38. Epidemiological Aspects of Cutaneous Leishmaniasis in Iran, Archives of Clinical Infectious Diseases (2015)
39. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
40. Evaluation of Community Interventions in Changes in Incidence of Cutaneous Leishmaniasis in Isfahan Province From 2002 to 2018: An Interrupted Time Series Regression Analysis, Iranian Journal of Epidemiology (2021)
41. Identification of Leishmania Species and Treatment Courses in Patients With Leishmaniasis in Isfahan, Iran, Journal of Isfahan Medical School (2012)
42. Behaviors and Perceptions Related to Cutaneous Leishmaniasis in Endemic Areas of the World: A Review, Acta Tropica (2021)
43. Treatment of Cutaneous Leishmaniasis With Aminosidine (Paromomycin) Ointment: Double-Blind, Randomized Trial in the Islamic Republic of Iran, Bulletin of the World Health Organization (2003)
44. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Isfahan Medical School (2014)
45. Pcr-Rflp Diagnosis and Characterization of Leishmania Species Causing Human Cutaneous Leishmaniasis and Evaluation of Treatment Times With Glucantime in These Patients, Tropical Biomedicine (2016)
46. The Comparison Between Trichloroacetic Acid 50% and Co2 Laser in the Treatment of Cutaneous Leishmaniasis Scar, Indian Journal of Dermatology (2011)
47. Distribution Frequency of Pathogenic Bacteria Isolated From Cutaneus Leishmaniasis Lesions, Korean Journal of Parasitology (2008)
48. Study of Il-12 Agonists in Macrophages From Patients With Healing and Non-Healing Forms of Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2013)
49. Comparison of Healing Effects of Local Injection of Glucantime With or Without Trichloroacetic Acid 50% in Cutaneous Leshmaniasis, Journal of Isfahan Medical School (2009)
50. A Randomized, Placebo-Controlled Trial of a Two-Week Regimen of Aminosidine (Paromomycin) Ointment for Treatment of Cutaneous Leishmaniasis in Iran, American Journal of Tropical Medicine and Hygiene (1995)